You searched for
Tag:
Research
Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
07/07/2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
05/05/2023
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12/04/2023
2022 for Chiesi: The Group’s international growth continues
05/04/2023
Restore to Impact - The next healthcare landmark for innovation and future-oriented competencies
01/03/2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
24/02/2023
Chiesi Group communicates that it is not involved in the events concerning the Holostem company
04/12/2022
Chiesi Group and Aptar partner to bring to market Disease Management Platform for Patients with Asthma and COPD
18/10/2022
Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
22/09/2022
First carbon minimal pMDI is on track with the goal to benefit patients and planet
27/07/2022
Solidarity actions to support the people affected by the war
08/04/2022
Chiesi Group continues to grow
31/03/2022
A new clinical framework redefines the diagnosis of COPD Exacerbations
16/12/2021
Chiesi Group focuses on biological drugs: an investment of 85 million euros for an international centre of excellence in Parma
14/12/2021
CLIMATE CHANGE – A MAJOR THREAT TO RESPIRATORY HEALTH IN EUROPE SAYS NEW REPORT FROM ECONOMIST INTELLIGENCE UNIT
07/09/2021